carnitine has been researched along with Chemical and Drug Induced Liver Injury in 66 studies
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study, the potential benefits of oral carnitine in preventing antituberculosis drug-induced hepatotoxicity (ATDH) were evaluated." | 9.19 | Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. ( Abdollahi, A; Dashti-Khavidaki, S; Hatamkhani, S; Jafari, S; Karimzadeh, I; Khalili, H, 2014) |
| "Valproic acid (VPA) as a widely used primary medication in the treatment of epilepsy is associated with reversible or irreversible hepatotoxicity." | 9.01 | Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. ( Chen, F; Guo, HL; Hu, YH; Jing, X; Lu, XP; Ni, MM; Qiu, JC; Sun, JY; Wang, T; Xu, ZJ, 2019) |
| "We could prove changes in acylcarnitine subspecies, which were associated with VPA treatment in children with epilepsy." | 7.74 | Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. ( Gerstner, T; Koenig, SA; Kohlmueller, D; Longin, E; Mehlem, P; Schulze, A; Teich, M; Treiss, I; Werner, T, 2007) |
| "In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy." | 7.70 | L-carnitine supplementation in childhood epilepsy: current perspectives. ( Bohan, TP; Coulter, DL; De Vivo, DC; Dreifuss, FE; Greenwood, RS; Nordli, DR; Shields, WD; Stafstrom, CE; Tein, I, 1998) |
| "In the present study, the potential benefits of oral carnitine in preventing antituberculosis drug-induced hepatotoxicity (ATDH) were evaluated." | 5.19 | Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. ( Abdollahi, A; Dashti-Khavidaki, S; Hatamkhani, S; Jafari, S; Karimzadeh, I; Khalili, H, 2014) |
| "Valproic acid (VPA) as a widely used primary medication in the treatment of epilepsy is associated with reversible or irreversible hepatotoxicity." | 5.01 | Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. ( Chen, F; Guo, HL; Hu, YH; Jing, X; Lu, XP; Ni, MM; Qiu, JC; Sun, JY; Wang, T; Xu, ZJ, 2019) |
| "Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world." | 4.90 | Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. ( Felker, D; Johnson, DE; Lynn, A; Wang, S, 2014) |
| "Children with refractory epilepsy who suffered from severe liver function impairment during valproic acid (VPA) treatment at routine dosage were studied." | 3.78 | [Valproic acid-induced idiosyncratic liver injury in 4 cases]. ( Bao, XH; Jiang, YW; Liu, CT; Qin, J; Wu, XP; Xiong, H; Zhang, YH; Zhao, H, 2012) |
| "We could prove changes in acylcarnitine subspecies, which were associated with VPA treatment in children with epilepsy." | 3.74 | Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. ( Gerstner, T; Koenig, SA; Kohlmueller, D; Longin, E; Mehlem, P; Schulze, A; Teich, M; Treiss, I; Werner, T, 2007) |
| "In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy." | 3.70 | L-carnitine supplementation in childhood epilepsy: current perspectives. ( Bohan, TP; Coulter, DL; De Vivo, DC; Dreifuss, FE; Greenwood, RS; Nordli, DR; Shields, WD; Stafstrom, CE; Tein, I, 1998) |
| "Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF)." | 2.82 | Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. ( Aithal, GP; Alvarez-Alvarez, I; Andrade, RJ; Arikan, C; Atallah, E; Lucena, MI; Medina-Caliz, I; Niu, H, 2022) |
| " An adverse effect of asparaginase includes hepatotoxicity, which can lead to severe liver failure and death." | 2.58 | Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature. ( Baker, WJ; Blackman, A; Boutin, A; Forcello, N; Shimanovsky, A, 2018) |
| "Levocarnitine is a mitochondrial co-factor that can potentially ameliorate the mitochondrial toxicity of asparaginase." | 2.58 | Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. ( Bleyer, A; Burke, MJ; DuVall, A; Flower, A; Hochberg, J; Madiwale, MV; McNeer, JL; Schulte, RR, 2018) |
| "Carnitine is an amino acid derivative that is an essential cofactor in the beta-oxidation of fatty acids." | 2.45 | Carnitine in the treatment of valproic acid-induced toxicity. ( Hantson, P; Lheureux, PE, 2009) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well tolerated, but rare serious complications may occur in some patients receiving VPA chronically, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity (VHT) and VPA-induced hyperammonaemic encephalopathy (VHE)." | 2.43 | Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? ( Gris, M; Lheureux, PE; Penaloza, A; Zahir, S, 2005) |
| "Carnitine was strongly recommended for children at risk of developing a carnitine deficiency." | 2.41 | The role of carnitine supplementation during valproic acid therapy. ( El-Chaar, GM; Raskind, JY, 2000) |
| " Idiosyncratic toxic responses are often not detected during this phase in development due to their relative rarity in incidence and differences in species sensitivity." | 2.41 | Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. ( Bacon, JA; Brass, EP; Cramer, CT; Petrella, DK; Sun, EL; Ulrich, RG, 2001) |
| " These deal mainly with biochemical systems that are known to be affected by VPA, or with the possible idiosyncratic production of toxic VPA metabolites, especially delta 4-VPA." | 2.38 | Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. ( Levy, RH; Stephens, JR, 1992) |
| "Carnitine is an important nutrient that is present in the diet (particularly in meat and dairy products) and is synthesized from dietary amino acids." | 2.38 | Carnitine, valproate, and toxicity. ( Coulter, DL, 1991) |
| "Methotrexate (MTX)-induced hepatotoxicity is a serious adverse effect that may limit its use." | 1.91 | The beneficial effects of l-carnitine and infliximab in methotrexate-induced hepatotoxicity: Emphasis on Notch1/Hes-1 signaling. ( Abbas, SS; Abdel-Latif, GA; Elmongy, NF; Radwan, SM; Wasfey, EF, 2023) |
| " Levocarnitine regimens varied widely; no adverse effects of levocarnitine were identified." | 1.62 | Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. ( Breese, EH; Burke, MJ; Hinson, A; Huynh, V; McNeer, JL; Mixon, BA; Orgel, E; Pierro, J; Rotz, S; Schulte, R, 2021) |
| "Acetaminophen (APAP) is a widely used analgesic." | 1.40 | Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans. ( Curry, SC; Jaeschke, H; Li, F; Ma, X; McGill, MR; Sharpe, MR; Williams, CD, 2014) |
| " In the following study, the relationship of acylcarnitines with other known indicators of APAP toxicity was examined in children receiving low-dose (therapeutic) and high-dose ('overdose' or toxic ingestion) exposure to APAP." | 1.40 | Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. ( Beger, RD; Bhattacharyya, S; Gill, P; James, LP; Kearns, GL; Letzig, LG; Marshall, JD; Pence, L; Reed, MD; Simpson, PM; Sullivan, JE; Van Den Anker, JN; Yan, K, 2014) |
| " A dose-response study showed that the accumulation of long-chain acylcarnitines in serum contributes to the separation of wild-type mice undergoing APAP-induced hepatotoxicity from other mouse groups in a multivariate model." | 1.35 | Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. ( Chen, C; Gonzalez, FJ; Idle, JR; Krausz, KW; Shah, YM, 2009) |
| "L-carnitine also has a prominent protective effect against AA toxicity and may be of therapeutic value in the treatment of AA-induced hepatotoxicity." | 1.34 | Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. ( Atakisi, O; Citil, M; Erginsoy, S; Karapehlivan, M; Kart, A; Tunca, R; Yapar, K, 2007) |
| "In patients with acute, infective and toxic hepatitis we have found levels of carnitine (25." | 1.28 | [Preliminary results on blood carnitine levels in children with hepatic pathology]. ( Angelotti, L; Bartelloni, M; Calevro, L; Ceccarelli, M; Lupetti, L; Nutini, P, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.06) | 18.7374 |
| 1990's | 14 (21.21) | 18.2507 |
| 2000's | 19 (28.79) | 29.6817 |
| 2010's | 21 (31.82) | 24.3611 |
| 2020's | 8 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Schulte, R | 1 |
| Hinson, A | 1 |
| Huynh, V | 1 |
| Breese, EH | 1 |
| Pierro, J | 1 |
| Rotz, S | 1 |
| Mixon, BA | 1 |
| McNeer, JL | 2 |
| Burke, MJ | 2 |
| Orgel, E | 1 |
| Khatab, LA | 1 |
| Abdel-Raheem, IT | 1 |
| Ghoneim, AI | 1 |
| Ahmed, SA | 1 |
| Abd El Reheem, MH | 1 |
| Elbahy, DA | 1 |
| Niu, H | 1 |
| Atallah, E | 1 |
| Alvarez-Alvarez, I | 1 |
| Medina-Caliz, I | 1 |
| Aithal, GP | 1 |
| Arikan, C | 1 |
| Andrade, RJ | 1 |
| Lucena, MI | 1 |
| Defina, M | 1 |
| Lazzarotto, D | 1 |
| Guolo, F | 1 |
| Minetto, P | 1 |
| Fracchiolla, NS | 1 |
| Giglio, F | 1 |
| Forghieri, F | 1 |
| Vitale, A | 1 |
| Chiaretti, S | 1 |
| Papayannidis, C | 1 |
| Piccini, M | 1 |
| Mulè, A | 1 |
| Bocchia, M | 1 |
| Leoncin, M | 1 |
| Gurrieri, C | 1 |
| Aprile, L | 1 |
| Lunghi, M | 1 |
| Bonifacio, M | 1 |
| Pasciolla, C | 1 |
| Cerrano, M | 1 |
| Fumagalli, M | 1 |
| Foà, R | 1 |
| Candoni, A | 1 |
| Radwan, SM | 1 |
| Abdel-Latif, GA | 1 |
| Abbas, SS | 1 |
| Elmongy, NF | 1 |
| Wasfey, EF | 1 |
| Jiang, T | 2 |
| Zhang, Y | 1 |
| Bai, M | 2 |
| Li, P | 2 |
| Wang, W | 2 |
| Chen, M | 1 |
| Ma, Z | 1 |
| Zeng, S | 1 |
| Zhou, H | 2 |
| Jiang, H | 2 |
| Kim, G | 1 |
| Choi, HK | 1 |
| Lee, H | 1 |
| Moon, KS | 1 |
| Oh, JH | 1 |
| Lee, J | 1 |
| Shin, JG | 1 |
| Kim, DH | 1 |
| Tamai, Y | 1 |
| Chen, Z | 1 |
| Wu, Y | 1 |
| Okabe, J | 1 |
| Kobayashi, Y | 3 |
| Chiba, H | 1 |
| Hui, SP | 1 |
| Eguchi, A | 1 |
| Iwasa, M | 1 |
| Ito, M | 1 |
| Takei, Y | 1 |
| Blackman, A | 1 |
| Boutin, A | 1 |
| Shimanovsky, A | 1 |
| Baker, WJ | 1 |
| Forcello, N | 1 |
| Schulte, RR | 1 |
| Madiwale, MV | 1 |
| Flower, A | 1 |
| Hochberg, J | 1 |
| DuVall, A | 1 |
| Bleyer, A | 1 |
| Yang, XN | 1 |
| Liu, XM | 1 |
| Fang, JH | 1 |
| Zhu, X | 1 |
| Yang, XW | 1 |
| Xiao, XR | 1 |
| Huang, JF | 1 |
| Gonzalez, FJ | 3 |
| Li, F | 3 |
| Li, C | 1 |
| Wang, Z | 1 |
| Li, L | 2 |
| Liu, Y | 1 |
| Janke, LJ | 1 |
| Relling, MV | 1 |
| Guo, HL | 1 |
| Jing, X | 1 |
| Sun, JY | 1 |
| Hu, YH | 1 |
| Xu, ZJ | 1 |
| Ni, MM | 1 |
| Chen, F | 1 |
| Lu, XP | 1 |
| Qiu, JC | 1 |
| Wang, T | 1 |
| McGill, MR | 1 |
| Sharpe, MR | 1 |
| Williams, CD | 1 |
| Curry, SC | 1 |
| Ma, X | 2 |
| Jaeschke, H | 1 |
| Roesmann, A | 1 |
| Afify, M | 1 |
| Panse, J | 1 |
| Eisert, A | 1 |
| Steitz, J | 1 |
| Tolba, RH | 1 |
| Hatamkhani, S | 1 |
| Khalili, H | 1 |
| Karimzadeh, I | 1 |
| Dashti-Khavidaki, S | 1 |
| Abdollahi, A | 1 |
| Jafari, S | 1 |
| Cetinkaya, A | 1 |
| Kantarceken, B | 1 |
| Bulbuloglu, E | 1 |
| Kurutas, EB | 1 |
| Ciralik, H | 1 |
| Atli, Y | 1 |
| Felker, D | 1 |
| Lynn, A | 1 |
| Wang, S | 1 |
| Johnson, DE | 1 |
| Bhattacharyya, S | 1 |
| Yan, K | 1 |
| Pence, L | 1 |
| Simpson, PM | 1 |
| Gill, P | 1 |
| Letzig, LG | 1 |
| Beger, RD | 1 |
| Sullivan, JE | 1 |
| Kearns, GL | 1 |
| Reed, MD | 1 |
| Marshall, JD | 1 |
| Van Den Anker, JN | 1 |
| James, LP | 1 |
| Yu, J | 1 |
| Jiang, YS | 1 |
| Jiang, Y | 1 |
| Peng, YF | 1 |
| Sun, Z | 1 |
| Dai, XN | 1 |
| Cao, QT | 1 |
| Sun, YM | 1 |
| Han, JC | 1 |
| Gao, YJ | 1 |
| Zheng, Z | 1 |
| Gelling, RW | 1 |
| Arafa, HM | 1 |
| Chen, C | 1 |
| Krausz, KW | 2 |
| Shah, YM | 1 |
| Idle, JR | 1 |
| Lheureux, PE | 2 |
| Hantson, P | 1 |
| Shaker, ME | 1 |
| Houssen, ME | 1 |
| Abo-Hashem, EM | 1 |
| Ibrahim, TM | 1 |
| Ozsoy, SY | 1 |
| Ozsoy, B | 1 |
| Ozyildiz, Z | 1 |
| Aytekin, I | 1 |
| Cheng, J | 1 |
| Xiong, H | 1 |
| Liu, CT | 1 |
| Zhang, YH | 1 |
| Bao, XH | 1 |
| Jiang, YW | 1 |
| Zhao, H | 1 |
| Wu, XP | 1 |
| Qin, J | 1 |
| Zeidán, Q | 1 |
| Strauss, M | 1 |
| Porras, N | 1 |
| Anselmi, G | 1 |
| Spaniol, M | 1 |
| Kaufmann, P | 1 |
| Beier, K | 1 |
| Wüthrich, J | 1 |
| Török, M | 1 |
| Scharnagl, H | 1 |
| März, W | 1 |
| Krähenbühl, S | 2 |
| Tein, I | 3 |
| Penaloza, A | 1 |
| Zahir, S | 1 |
| Gris, M | 1 |
| Werner, T | 1 |
| Treiss, I | 1 |
| Kohlmueller, D | 1 |
| Mehlem, P | 1 |
| Teich, M | 1 |
| Longin, E | 1 |
| Gerstner, T | 1 |
| Koenig, SA | 1 |
| Schulze, A | 1 |
| Al-Majed, AA | 1 |
| Igoudjil, A | 1 |
| Abbey-Toby, A | 1 |
| Begriche, K | 1 |
| Grodet, A | 1 |
| Chataigner, K | 1 |
| Peytavin, G | 1 |
| Maachi, M | 1 |
| Colin, M | 1 |
| Robin, MA | 1 |
| Lettéron, P | 1 |
| Feldmann, G | 1 |
| Pessayre, D | 1 |
| Fromenty, B | 1 |
| Yapar, K | 1 |
| Kart, A | 1 |
| Karapehlivan, M | 1 |
| Atakisi, O | 1 |
| Tunca, R | 1 |
| Erginsoy, S | 1 |
| Citil, M | 1 |
| Goto, S | 1 |
| Seo, T | 1 |
| Hagiwara, T | 1 |
| Ueda, K | 1 |
| Yamauchi, T | 1 |
| Nagata, S | 1 |
| Ando, Y | 1 |
| Ishitsu, T | 1 |
| Nakagawa, K | 1 |
| Björnsson, E | 1 |
| Bernardi, M | 1 |
| Bertolini, A | 1 |
| Ferrari, F | 1 |
| Greggia, A | 1 |
| Mang, G | 1 |
| Kupferschmidt, H | 1 |
| Meier, PJ | 1 |
| Krause, M | 1 |
| Chanda, S | 2 |
| Mehendale, M | 1 |
| Bertelli, A | 1 |
| Cerrati, A | 1 |
| Giovannini, L | 1 |
| Mian, M | 1 |
| Spaggiari, P | 1 |
| Bertelli, AA | 1 |
| Murphy, JV | 1 |
| Groover, RV | 1 |
| Hodge, C | 1 |
| Mehendale, HM | 1 |
| Böhles, H | 1 |
| Sewell, AC | 1 |
| Wenzel, D | 1 |
| De Vivo, DC | 1 |
| Bohan, TP | 2 |
| Coulter, DL | 2 |
| Dreifuss, FE | 1 |
| Greenwood, RS | 1 |
| Nordli, DR | 1 |
| Shields, WD | 1 |
| Stafstrom, CE | 1 |
| Kuratsune, H | 1 |
| Yamaguti, K | 1 |
| Lindh, G | 1 |
| Evengard, B | 1 |
| Takahashi, M | 1 |
| Machii, T | 1 |
| Matsumura, K | 1 |
| Takaishi, J | 1 |
| Kawata, S | 1 |
| Långström, B | 1 |
| Kanakura, Y | 1 |
| Kitani, T | 1 |
| Watanabe, Y | 1 |
| Kibayashi, M | 1 |
| Nagao, M | 1 |
| Chiba, S | 1 |
| Raskind, JY | 1 |
| El-Chaar, GM | 1 |
| Ulrich, RG | 1 |
| Bacon, JA | 1 |
| Brass, EP | 1 |
| Cramer, CT | 1 |
| Petrella, DK | 1 |
| Sun, EL | 1 |
| Helton, E | 1 |
| McDonald, I | 1 |
| König, S | 1 |
| Gazitt, S | 1 |
| Sugimoto, T | 3 |
| Scheffner, D | 1 |
| Cusmano, L | 1 |
| Li, S | 1 |
| Koch, G | 1 |
| DeVivo, DC | 1 |
| Stephens, JR | 1 |
| Levy, RH | 1 |
| Willmore, LJ | 1 |
| Triggs, WJ | 1 |
| Pellock, JM | 1 |
| Nishida, N | 2 |
| Murakami, K | 2 |
| Woo, M | 2 |
| Sakane, Y | 2 |
| Yasuhara, A | 1 |
| Shuto, H | 1 |
| Hatanaka, T | 1 |
| Araki, A | 1 |
| Ceccarelli, M | 1 |
| Nutini, P | 1 |
| Calevro, L | 1 |
| Angelotti, L | 1 |
| Lupetti, L | 1 |
| Bartelloni, M | 1 |
| Cotariu, D | 1 |
| Zaidman, JL | 1 |
| Munro, IC | 1 |
| Salem, FA | 1 |
| Goodman, T | 1 |
| Hasnain, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia[NCT05501899] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-03-03 | Recruiting | ||
| The Efficacy of L-Carnitine in the Management of Acute Clozapine Intoxication[NCT05632094] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study[NCT05881928] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-07-25 | Not yet recruiting | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
16 reviews available for carnitine and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adrenal Cortex Hormones; Adult; Carnitine; Chemical and D | 2022 |
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Femal | 2018 |
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carnitine; Chemical and Drug In | 2018 |
Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.
Topics: Anticonvulsants; Antioxidants; Carnitine; Chemical and Drug Induced Liver Injury; Epilepsy; Humans; | 2019 |
Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Carnitine; Chemical and Drug Induced Liver Injury; Child | 2014 |
Carnitine in the treatment of valproic acid-induced toxicity.
Topics: Animals; Anticonvulsants; Antidotes; Carnitine; Chemical and Drug Induced Liver Injury; Energy Metab | 2009 |
Role of carnitine and fatty acid oxidation and its defects in infantile epilepsy.
Topics: Acyl-CoA Dehydrogenase; Anticonvulsants; Carnitine; Carrier Proteins; Chemical and Drug Induced Live | 2002 |
Carnitine transport: pathophysiology and metabolism of known molecular defects.
Topics: Animals; Biological Transport; Carnitine; Carrier Proteins; Chemical and Drug Induced Liver Injury; | 2003 |
Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Drug Overdose; Hepatic Encephalo | 2005 |
Hepatotoxicity associated with antiepileptic drugs.
Topics: Acetylcysteine; Animals; Anticonvulsants; Autoimmune Diseases; Carnitine; Chemical and Drug Induced | 2008 |
The role of carnitine supplementation during valproic acid therapy.
Topics: Adolescent; Adult; Aged; Ammonia; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury | 2000 |
Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon.
Topics: Animals; Anti-Anxiety Agents; Carnitine; Cell Hypoxia; Cells, Cultured; Chemical and Drug Induced Li | 2001 |
Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.
Topics: Ammonia; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Humans; Liver; Liver Diseases; | 1992 |
Valproate toxicity: risk-screening strategies.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Enzymes; Epilepsy; Hepatic Encephalopathy; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Carnitine, valproate, and toxicity.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Child; Epilepsy; Hepatic Encephalopathy; Humans; | 1991 |
Valproic acid and the liver.
Topics: Amino Acids; Carnitine; Chemical and Drug Induced Liver Injury; Drug Interactions; Fatty Acids; Huma | 1988 |
3 trials available for carnitine and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferase | 2014 |
Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Body Weight; Carnitine; Chemical and Drug Induced Liver | 2008 |
The effect of carnitine supplementation in valproate-induced hyperammonaemia.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Chil | 1996 |
47 other studies available for carnitine and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver I | 2021 |
Protective effects of melatonin and L-carnitine against methotrexate-induced toxicity in isolated rat hepatocytes.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Carniti | 2022 |
l-Carnitine ameliorates the osteoporotic changes and protects against simvastatin induced myotoxicity and hepatotoxicity in glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Carnitine; Chemical and Drug Induced Liver Injury; Glucocorticoids; Myotoxicity; Osteoporos | 2022 |
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Dieta | 2022 |
The beneficial effects of l-carnitine and infliximab in methotrexate-induced hepatotoxicity: Emphasis on Notch1/Hes-1 signaling.
Topics: Animals; Anti-Inflammatory Agents; Carnitine; Chemical and Drug Induced Liver Injury; Infliximab; Li | 2023 |
Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.
Topics: Adult; Animals; Antipsychotic Agents; Carnitine; Chemical and Drug Induced Liver Injury; Coenzyme A | 2019 |
Increased hepatic acylcarnitines after oral administration of amiodarone in rats.
Topics: Administration, Oral; Amiodarone; Animals; Biomarkers; Carnitine; Chemical and Drug Induced Liver In | 2020 |
Branched-chain amino acids and l-carnitine attenuate lipotoxic hepatocellular damage in rat cirrhotic liver.
Topics: Amino Acids, Branched-Chain; Animals; Carbon Tetrachloride; Carnitine; Cell Death; Chemical and Drug | 2021 |
PPARα Mediates the Hepatoprotective Effects of Nutmeg.
Topics: Animals; Carnitine; Chemical and Drug Induced Liver Injury; Lipids; Metabolomics; Mice; Mice, Knocko | 2018 |
Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice.
Topics: Animals; Antipsychotic Agents; Carnitine; Cell Line; Chemical and Drug Induced Liver Injury; Clozapi | 2019 |
L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model.
Topics: Animals; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Dis | 2019 |
Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans.
Topics: Acetaminophen; Acetylcysteine; Animals; Antidotes; Biomarkers; Carnitine; Chemical and Drug Induced | 2014 |
L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers.
Topics: Animals; Asparaginase; Aspartate Aminotransferases; Blood Pressure; Carnitine; Cell Line, Tumor; Che | 2013 |
The effects of L-carnitine and N-acetylcysteine on carbontetrachloride induced acute liver damage in rats.
Topics: Acetylcysteine; Animals; Carbon Tetrachloride; Carnitine; Chemical and Drug Induced Liver Injury; Di | 2013 |
Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Age Factors; Alanine Transaminase; Biomarkers; Carnitine; | 2014 |
Targeted metabolomic study indicating glycyrrhizin’s protection against acetaminophen-induced liver damage through reversing fatty acid metabolism.
Topics: Acetaminophen; Alanine Transaminase; Animals; Aspartate Aminotransferases; Carnitine; Chemical and D | 2014 |
Attenuation of Carbon Tetrachloride-Induced Hepatic Toxicity by a Dietary Supplement.
Topics: Alanine Transaminase; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Animals; Aspartate Aminotr | 2017 |
Carnitine deficiency: a possible risk factor in paracetamol hepatotoxicity.
Topics: Acetaminophen; Alanine Transaminase; Alkaline Phosphatase; Analgesics, Non-Narcotic; Animals; Aspart | 2009 |
Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.
Topics: Acetaminophen; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; C | 2009 |
Comparison of vitamin E, L-carnitine and melatonin in ameliorating carbon tetrachloride and diabetes induced hepatic oxidative stress.
Topics: Animals; Antioxidants; Blood Glucose; Carbon Tetrachloride Poisoning; Carnitine; Chemical and Drug I | 2009 |
Protective effect of L-carnitine on experimental lead toxicity in rats: a clinical, histopathological and immunohistochemical study.
Topics: Animals; Blood Cells; Brain Diseases; Carnitine; Chemical and Drug Induced Liver Injury; Enzymes; He | 2011 |
CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.
Topics: Animals; Antitubercular Agents; Bile Acids and Salts; Biological Transport; Carnitine; Chemical and | 2013 |
[Valproic acid-induced idiosyncratic liver injury in 4 cases].
Topics: Anticonvulsants; Biomarkers; Carnitine; Chemical and Drug Induced Liver Injury; Child; Child, Presch | 2012 |
Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cardiomyopathies; Carnitine; Chemical and Drug | 2002 |
Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate.
Topics: Acyl-CoA Oxidase; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Electron Transport; Ke | 2003 |
Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Chemical and Drug Induced Liver Injury; Child | 2007 |
Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats.
Topics: Adenosine Triphosphate; Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2007 |
High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice.
Topics: Adipose Tissue, White; Administration, Oral; Aminoisobutyric Acids; Animals; Carnitine; Chemical and | 2007 |
Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice.
Topics: Acetaminophen; Acute Disease; Alanine Transaminase; Analgesics, Non-Narcotic; Animals; Aspartate Ami | 2007 |
[Activation of the acetylation in vivo of sulfamide by DL-acetylcarnitine].
Topics: Acetates; Animals; Carbon Tetrachloride Poisoning; Carnitine; Chemical and Drug Induced Liver Injury | 1967 |
Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity.
Topics: Adult; Carnitine; Chemical and Drug Induced Liver Injury; Coenzyme A; Fatal Outcome; Female; Humans; | 1995 |
Role of nutritional fatty acid and L-carnitine in the final outcome of thioacetamide hepatotoxicity.
Topics: Analysis of Variance; Animals; Carnitine; Cell Division; Chemical and Drug Induced Liver Injury; Die | 1994 |
Protective action of L-carnitine and coenzyme Q10 against hepatic triglyceride infiltration induced by hyperbaric oxygen and ethanol.
Topics: Animals; Carnitine; Chemical and Drug Induced Liver Injury; Drug Synergism; Ethanol; Glutathione; Hy | 1993 |
Hepatotoxic effects in a child receiving valproate and carnitine.
Topics: Carnitine; Chemical and Drug Induced Liver Injury; Humans; Infant; Male; Treatment Failure; Valproic | 1993 |
Role of nutrition in the survival after hepatotoxic injury.
Topics: Administration, Oral; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Diet; Drinking; Gl | 1996 |
L-carnitine supplementation in childhood epilepsy: current perspectives.
Topics: Age Factors; Ammonia; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Child; Chi | 1998 |
Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases.
Topics: Acute Disease; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Fatigu | 1998 |
Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenase, Long-Chain; Animals; Anticonvulsants; Carnitine; Che | 1999 |
Effect of L-carnitine treatment for valproate-induced hepatotoxicity.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; | 2001 |
Effect of L-carnitine treatment for valproate-induced hepatotoxicity.
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Epilepsy; Humans; Liver Diseases | 2002 |
Valproate-induced hepatoxicity: protective effect of L-carnitine supplementation.
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Dose-Re | 1990 |
Carnitine metabolism and morphometric change of liver mitochondria in valproate-treated rats.
Topics: Animals; Carnitine; Chemical and Drug Induced Liver Injury; Male; Mitochondria, Liver; Muscles; Rats | 1990 |
[Preliminary results on blood carnitine levels in children with hepatic pathology].
Topics: Adolescent; Carnitine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Hepa | 1989 |
Biochemical and pathological changes in the heart and liver of rats given brominated cottonseed oil.
Topics: Adenosine Triphosphate; Animals; Bromine; Carbon Isotopes; Carnitine; Chemical and Drug Induced Live | 1971 |